Engineered NKG2C ⁺ NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome

Abstract excerpt

Engineered T and NK cell therapies have widely been used to treat hematologic malignancies and solid tumors, with promising clinical results. Current chimeric antigen receptor (CAR) T cell therapeutics have, however, been associated with treatment-related adverse events such as cytokine release syndrome (CRS) and are prone to immunologic exhaustion. CAR-NK therapeutics, while not associated with CRS, have limited...

Topics

Open a Topic to create a Post that cites this publication.

• CAR-T cell therapy research
• CRISPR and Genetic Engineering
• Immune Cell Function and Interaction
• Immunotherapy and Immune Responses
• RNA Interference and Gene Delivery
• T-cell and B-cell Immunology
• Virus-based gene therapy research

Identifiers and source

Literature Corpus work

76b9b2d7-dd9c-5593-a72e-cfb53f995bd6

DOI

10.1101/2024.07.16.603785